Lisdexamfetamine Dimesylate Chewable Tablet Shortage: Current Availability and Manufacturer Updates
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Lisdexamfetamine Dimesylate chewable tablets, with some manufacturers noting limited supplies across multiple dosage strengths.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Lisdexamfetamine-Dimesylate.
Lisdexamfetamine Dimesylate Chewable Tablet Shortage: Current Availability and Manufacturer Updates
What's in Shortage
The FDA has identified a current shortage of Lisdexamfetamine Dimesylate in chewable tablet form. This medication, which falls under the therapeutic category of Psychiatry, is used by patients for various psychiatric conditions. The shortage was initially posted on July 14, 2023, and the status was most recently updated on February 3, 2026.
Which Manufacturers Are Affected
Currently, two manufacturers are supplying the market, though availability may vary by location and dosage strength.
Novadoz Pharmaceuticals LLC
- Status: Available (Note: Limited supply from Manufacturers)
- Presentations: 10 mg (NDC 72205-132-91), 20 mg (NDC 72205-133-91), 30 mg (NDC 72205-134-91), 40 mg (NDC 72205-135-91), 50 mg (NDC 72205-136-91), and 60 mg (NDC 72205-137-91).
- Contact Info: (855) 668-2369; customerservice@novadozpharma.com
Sun Pharmaceutical Industries, Inc.
- Status: Available
- Presentations: 10 mg (NDC 57664-083-88), 20 mg (NDC 57664-084-88), 30 mg (NDC 57664-085-88), 40 mg (NDC 57664-086-88), 50 mg (NDC 57664-087-88), and 60 mg (NDC 57664-088-88).
- Contact Info: 800-818-4555
Why There's a Shortage
The FDA source data does not provide a specific reason for the current supply limitations or the limited supply reported by manufacturers.
What Patients Should Do
If you are prescribed Lisdexamfetamine Dimesylate chewable tablets and are having difficulty filling your prescription, consider the following steps:
- Speak with your pharmacist: They can provide information on current stock levels or check if the medication is available at other nearby locations.
- Consult your healthcare provider: Discuss your treatment options and ask about potential alternatives if your specific dosage is unavailable.
- Contact the manufacturers: You may use the contact information listed above to inquire about the availability of specific lots or presentations.
Disclaimer: Patients should always consult with their healthcare provider or pharmacist regarding medical concerns or changes to their medication regimen.
Source
Attribution: FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.